Seneca Biopharma (NASDAQ: SNCA) and Leading Biosciences said on Thursday that they have entered into a definitive merger agreement which will see a wholly-owned subsidiary of Seneca merge with Leading Biosciences in an all-stock transaction.
In a statement, the companies said that the new combined company will focus on advancing Leading’s lead pipeline asset, LB1148, in clinical studies to evaluate its potential.
Upon completion of the deal, the company is expected to operate under the name Palisade Bio inc and trade on the Nasdaq under the ticker symbol PALI.
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Explore stocks with XTB →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to invest in the stocks making the news?
Go from following the market to investing in it, with access to thousands
of stocks across major UK and international markets.
See available stocks →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Own the stocks you’re reading about
Invest in real shares across the UK, US and other major global markets
through XTB, all from one investment account.
Explore XTB shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
You don’t need to buy a whole share
Fractional shares let you invest from just £1, giving you more control
over how much you put into individual companies.
Explore fractional shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to see how XTB works first?
Explore the platform with an XTB demo account before deciding whether
you want to invest with real money.
Try the XTB demo →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Seneca shareholders will own approximately 26.2% of the combined company while Leading Biosciences shareholders will own about 73.8% of the combined company on a fully diluted basis.
Shareholders of Seneca will also receive one contingent value right for each share of Seneca common stock as a dividend.
Investment firm Altium Capital has agreed to invest $22.5 million once the merger is completed.
“Following an extensive review of strategic alternatives, we believe that this merger with Leading BioSciences is in the best interest of Seneca’s stockholders, and has the potential to deliver both near- and long-term value to the stockholders,” commented Kenneth C Carter, executive chairman of Seneca.
Seneca’s stock price initially surged 61% following the merger news. It is currently trading 44.26% higher at $1.12 per share ahead of the US opening bell.
